Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration

Ophthalmology and Therapy - United Kingdom
doi 10.1007/s40123-016-0075-1
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Role of Interleukin 33 in Neovascular Age-Related Macular Degeneration

The Lancet
Medicine
2016English

Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2017English

Treatment of Age-Related Neovascular Macular Degeneration: The Patient’s Perspective

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2017English

Mineralocorticoid Receptor Antagonism Limits Experimental Choroidal Neovascularization and Structural Changes Associated With Neovascular Age-Related Macular Degeneration

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2016English

Neovascular Age-Related Macular Degeneration Is Associated With Cataract Surgery

Acta Ophthalmologica
MedicineOphthalmology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy